Saluda Medical has announced the full US commercial launch of its EVA sensing technology intended for scanning and analysing the spinal cord.

UroMems is set to enter the pivotal trial phase with its device for treating stress urinary incontinence (SUI).

Xeltis has reported positive preliminary data for its Xabg coronary artery bypass conduit (CABG) in a trial that is underway at EU sites.

Medtronic has announced the first subject enrolment in the PELE trial, aiming to assess the Onyx liquid embolic system (LES).

The US Food and Drug Administration (FDA) has granted 510(k) clearance for Tempus AI’s ECG-Low (ejection fraction) EF software.

The medical device industry faces being pulled into a broader contest over control, sovereignty and industrial self-sufficiency.

Varian has introduced the next-generation microwave ablation solution, IntelliBlate, in Europe to treat soft tissue tumours.

Bio-Techne has announced a collaboration to distribute Spear Bio’s advanced SPEAR UltraDetect immunoassays globally.

BD has reached an agreement to merge its Biosciences & Diagnostic Solutions business with Waters Corporation in a nearly $17.5bn deal.

Zimmer Biomet has signed a definitive agreement to acquire orthopaedic robotics company Monogram Technologies.

With the aim of being the largest life sector by 2035 behind only the US and China, the UK government is ramping up commercialisation.

Viome, with Scripps Research, is set to develop and clinically validate the first RNA test for detecting precancerous colon polyps.